Login to Your Account

Zafgen files $86.25M IPO to advance obesity candidate beloranib

By Marie Powers
Staff Writer

Tuesday, April 22, 2014
Zafgen Inc. defied recent trends to downsize biotech initial public offerings (IPO) by filing with the SEC to seek a raise of up to $86.25 million, excluding overallotments. If the offering amount stands, Zafgen would slide into a tie with Radius Health Inc. for third place among 22 biotechs sitting in the IPO queue, according to BioWorld Snapshots, behind Alder Biopharmaceuticals Inc. and Intra-Cellular Therapies Inc., which filed to raise $115 million apiece.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription